{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:54:58Z","timestamp":1792270498880,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cepharanthine (CEP) is a naturally occurring alkaloid derived from <jats:italic>Stephania cepharantha<\/jats:italic> Hayata and demonstrated to have unique anti-inflammatory, antioxidative, immunomodulating, antiparasitic, and antiviral properties. Its therapeutic potential as an antiviral agent has never been more important than in combating COVID-19 caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) virus. Cepharanthine suppresses nuclear factor-kappa B (NF-\u03baB) activation, lipid peroxidation, nitric oxide (NO) production, cytokine production, and expression of cyclooxygenase; all of which are crucial to viral replication and inflammatory response. Against SARS-CoV-2 and homologous viruses, CEP predominantly inhibits viral entry and replication at low doses; and was recently identified as the most potent coronavirus inhibitor among 2406 clinically approved drug repurposing candidates in a preclinical model. This review critically analyzes and consolidates available evidence establishing CEP\u2019s potential therapeutic importance as a drug of choice in managing COVID-19 cases.<\/jats:p>","DOI":"10.1007\/s43440-020-00132-z","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T17:03:46Z","timestamp":1595437426000},"page":"1509-1516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19"],"prefix":"10.1007","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5643-0945","authenticated-orcid":false,"given":"Moshe","family":"Rogosnitzky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0805-3142","authenticated-orcid":false,"given":"Paul","family":"Okediji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4860-9830","authenticated-orcid":false,"given":"Igor","family":"Koman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"132_CR1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.14.039925","author":"H Ohashi","year":"2020","unstructured":"Ohashi H, Watashi K, Saso W, Shionoya K, Iwanami S, Hirokawa T, et al. Multidrug treatment with nelfinavir and cepharanthine against COVID-19. BioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.04.14.039925.","journal-title":"BioRxiv"},{"issue":"7798","key":"132_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270\u20133.","journal-title":"Nature"},{"key":"132_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1734-1140(11)70500-X","volume":"63","author":"M Rogosnitzky","year":"2011","unstructured":"Rogosnitzky M, Danks R. Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions. Pharmacol Rep. 2011;63:337\u201347.","journal-title":"Pharmacol Rep"},{"key":"132_CR4","doi-asserted-by":"publisher","first-page":"152956","DOI":"10.1016\/j.phymed.2019.152956","volume":"62","author":"C Bailly","year":"2019","unstructured":"Bailly C. Cepharanthine: an update of its mode of action, pharmacological properties and medical applications. Phytomedicine. 2019;62:152956.","journal-title":"Phytomedicine"},{"issue":"11","key":"132_CR5","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3390\/biom9110696","volume":"9","author":"DE Kim","year":"2019","unstructured":"Kim DE, Min JS, Jang MS, Lee JY, Shin YS, Park CM, et al. Natural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43 infection of MRC-5 human lung cells. Biomolecules. 2019;9(11):696.","journal-title":"Biomolecules"},{"issue":"6","key":"132_CR6","first-page":"493","volume":"118","author":"CH Zhang","year":"2005","unstructured":"Zhang CH, Wang YF, Liu XJ, Lu JH, Qian CW, Wan ZY, et al. Antiviral activity of cepharanthine against severe acute respiratory syndrome coronavirus in vitro. Chin Med J. 2005;118(6):493\u20136.","journal-title":"Chin Med J"},{"issue":"9","key":"132_CR7","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/CM9.0000000000000797","volume":"133","author":"HH Fan","year":"2020","unstructured":"Fan HH, Wang LQ, Liu WL, An XP, Liu ZD, He XQ, et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model. Chin Med J. 2020;133(9):1051\u20136.","journal-title":"Chin Med J"},{"key":"132_CR8","unstructured":"Food and Drug Administration. Coronavirus (COVID-19) Update: FDA issues emergency use authorization for potential COVID-19 treatment. FDA News Release [Internet]. 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment. Accessed 21 June 2020."},{"key":"132_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6019","author":"JM Sanders","year":"2020","unstructured":"Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review.\u00a0JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.6019.","journal-title":"JAMA"},{"key":"132_CR10","unstructured":"Food and Drug Administration. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine [Internet]. 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and. Accessed 21 June 2020."},{"key":"132_CR11","first-page":"233","volume-title":"The alkaloids chemistry and physiology","author":"M Kulka","year":"1965","unstructured":"Kulka M. Bisbenzylisoquinoline alkaloids. In: Manske R, editor. The alkaloids chemistry and physiology. London: Academic Press; 1965. p. 233."},{"issue":"1","key":"132_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0005-2736(82)90226-7","volume":"691","author":"S Nagatsuka","year":"1982","unstructured":"Nagatsuka S, Nakazawa T. Effects of membrane-stabilizing agents, cholesterol and cepharanthine, on radiation-induced lipid peroxidation and permeability in liposomes. Biochim Biophys Acta (BBA)-Biomembr. 1982;691(1):171\u20137.","journal-title":"Biochim Biophys Acta (BBA)-Biomembr"},{"issue":"7","key":"132_CR13","first-page":"1063","volume":"31","author":"S Nomoto","year":"2004","unstructured":"Nomoto S, Imada H, Ohguri T, Yahara K, Kato F, Morioka T, et al. Effect of Cepharanthine in preventing radiation induced normal tissue damage in prostate cancer. Gan To Kagaku Ryoho. 2004;31(7):1063\u20136.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"3","key":"132_CR14","first-page":"408","volume":"33","author":"S Nakayama","year":"1992","unstructured":"Nakayama S, Matsushita A, Ichiba S, Nagai K. Clinical evaluation of cepharanthin for chronic idiopathic thrombocytopenic purpura. Rinsho Ketsueki. 1992;33(3):408\u20139.","journal-title":"Rinsho Ketsueki"},{"issue":"4","key":"132_CR15","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3999\/jscpt.20.741","volume":"20","author":"K Yasuda","year":"1989","unstructured":"Yasuda K, Moro M, Akasu M, Ohnishi A. Pharmacokinetics of Cepharanthin in Phase I clinical trials (single and continuous intravenous administration). Jpn J Clin Pharmacol Ther. 1989;20(4):741\u20139.","journal-title":"Jpn J Clin Pharmacol Ther"},{"issue":"2","key":"132_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10753-013-9744-6","volume":"37","author":"Z Ershun","year":"2014","unstructured":"Ershun Z, Yunhe F, Zhengkai W, Yongguo C, Naisheng Z, Zhengtao Y. Cepharanthine attenuates lipopolysaccharide-induced mice mastitis by suppressing the NF-\u03baB signaling pathway. Inflammation. 2014;37(2):331\u20137.","journal-title":"Inflammation"},{"key":"132_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.tiv.2016.03.010","volume":"34","author":"KR Paudel","year":"2016","unstructured":"Paudel KR, Karki R, Kim D-W. Cepharanthine inhibits in vitro VSMC proliferation and migration and vascular inflammatory responses mediated by RAW2647. Toxicol In Vitro. 2016;34:16\u201325.","journal-title":"Toxicol In Vitro"},{"key":"132_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.intimp.2006.09.008","volume":"7","author":"S Sakaguchi","year":"2007","unstructured":"Sakaguchi S, Furusawa S, Wu J, Nagata K. Preventive effects of a biscoclaurine alkaloid, cepharanthine, on endotoxin or tumor necrosis factor-alpha-induced septic shock symptoms: involvement of from cell death in L929 cells and nitric oxide production in raw 264.7 cells. Int Immunopharmacol. 2007;7:191\u20137.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"132_CR19","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/0006-2952(90)90271-L","volume":"39","author":"M Tsuyoshi","year":"1990","unstructured":"Tsuyoshi M, Kunzoorita O, Keisuke E, Hirotsugu K, Eisuke FS, Bunji I, et al. Inhibition of active oxygen generation in guinea-pig neutrophils by biscoclaurine alkaloids. Biochem Pharmacol. 1990;39(7):1255\u20139.","journal-title":"Biochem Pharmacol"},{"key":"132_CR20","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1038\/srep05510","volume":"4","author":"BYK Law","year":"2014","unstructured":"Law BYK, Chan WK, Xu SW, Wang JR, Bai LP, Liu L, et al. Natural small-molecule enhancers of autophagy induce autophagic cell death in apoptosis-defective cells. Sci Rep. 2014;4:5510.","journal-title":"Sci Rep"},{"issue":"5","key":"132_CR21","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3892\/ijo_00000417","volume":"35","author":"K Harada","year":"2009","unstructured":"Harada K, Ferdous T, Itashiki Y, Takii M, Mano T, Mori Y, et al. Cepharanthine inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing expression of vascular endothelial growth factor and interleukin-8. Int J Oncol. 2009;35(5):1025\u201335.","journal-title":"Int J Oncol"},{"key":"132_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1475-2875-13-90","volume":"13","author":"C Desgrouas","year":"2014","unstructured":"Desgrouas C, Dormoi J, Chapus C, Ollivier E, Parzy D, Taudon N. In vitro and in vivo combination of cepharanthine with anti-malarial drugs. Malar J. 2014;13:90.","journal-title":"Malar J"},{"key":"132_CR23","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.bcp.2008.12.005","volume":"77","author":"Y Zhou","year":"2009","unstructured":"Zhou Y. Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. Biochem Pharmacol. 2009;77:993\u20131001.","journal-title":"Biochem Pharmacol"},{"key":"132_CR24","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1089\/aid.1998.14.1239","volume":"14","author":"M Okamoto","year":"1998","unstructured":"Okamoto M, Ono M, Baba M. Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. AIDS Res Hum Retroviruses. 1998;14:1239\u201345.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"132_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0166-3542(96)01010-8","volume":"33","author":"M Baba","year":"1997","unstructured":"Baba M. Cellular factors as alternative targets for inhibition of HIV-1. Antiviral Res. 1997;33(3):141\u201352.","journal-title":"Antiviral Res"},{"key":"132_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/095632020101200506","volume":"12","author":"M Baba","year":"2001","unstructured":"Baba M, Okamoto M, Kashiwaba N, Ono M. Anti-HIV-1 activity and structure-activity relationship of cepharanoline derivatives in chronically infected cells. Antivir Chem Chemother. 2001;12:307\u201312.","journal-title":"Antivir Chem Chemother"},{"key":"132_CR27","first-page":"458","volume":"17","author":"T Yokoshima","year":"1986","unstructured":"Yokoshima T, Tsutsumi S, Ohtsuki T, Takaichi M, Nakajima T, Akasu M. Studies on metabolic fate of cepharanthine absorption, distribution, metabolism and excretion in rats. Iyakuhin Kenkyu. 1986;17:458\u201379.","journal-title":"Iyakuhin Kenkyu"},{"issue":"7","key":"132_CR28","first-page":"2639","volume":"32","author":"M Toyama","year":"2012","unstructured":"Toyama M, Hamasaki T, Uto T, Aoyama H, Okamoto M, Hashmoto Y, et al. Synergistic inhibition of HTLV-1-infected cell proliferation by combination of cepharanthine and a tetramethylnaphthalene derivative. Anticancer Res. 2012;32(7):2639\u201345.","journal-title":"Anticancer Res"},{"issue":"4","key":"132_CR29","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1473-3099(09)70056-8","volume":"9","author":"M-F Yuen","year":"2009","unstructured":"Yuen M-F, Fung J, Wong DK-H, Lai C-L. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis. 2009;9(4):256\u201364.","journal-title":"Lancet Infect Dis"},{"issue":"1\u20133","key":"132_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejphar.2012.02.030","volume":"683","author":"YB Zhou","year":"2012","unstructured":"Zhou YB, Wang YF, Zhang Y, Zheng LY, Yang XA, Wang N, et al. In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates. Eur J Pharmacol. 2012;683(1\u20133):10\u20135.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"132_CR31","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cmi.2020.03.026","volume":"26","author":"N Petrosillo","year":"2020","unstructured":"Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26(6):729\u201334. https:\/\/doi.org\/10.1016\/j.cmi.2020.03.026.","journal-title":"Clin Microbiol Infect."},{"issue":"16","key":"132_CR32","doi-asserted-by":"publisher","first-page":"8824","DOI":"10.1128\/JVI.78.16.8824-8834.2004","volume":"78","author":"JR St-Jean","year":"2004","unstructured":"St-Jean JR, Jacomy H, Desforges M, Vabret A, Freymuth F, Talbot PJ. Human respiratory coronavirus OC43: genetic stability and neuroinvasion. J Virol. 2004;78(16):8824\u201334.","journal-title":"J Virol"},{"issue":"7807","key":"132_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215\u201320. https:\/\/doi.org\/10.1038\/s41586-020-2180-5.","journal-title":"Nature."},{"issue":"7","key":"132_CR34","doi-asserted-by":"publisher","first-page":"e00819","DOI":"10.1128\/AAC.00819-20","volume":"64","author":"S Jeon","year":"2020","unstructured":"Jeon S, Ko M, Lee J, et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother. 2020;64(7):e00819\u201320.","journal-title":"Antimicrob Agents Chemother."},{"key":"132_CR35","doi-asserted-by":"crossref","unstructured":"Ko M, Jeon S, Ryu WS, Kim S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate. bioRxiv [Internet]. 2020.\u00a0https:\/\/www.biorxiv.org\/content\/10.1101\/2020.05.12.090035v1.abstract. Accessed 21 June 2020.","DOI":"10.1101\/2020.05.12.090035"},{"key":"132_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26222","author":"Z Ruan","year":"2020","unstructured":"Ruan Z, Liu C, Guo Y, et al. SARS-CoV-2 and SARS-CoV: virtual screening of potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12). J Med Virol. 2020. https:\/\/doi.org\/10.1002\/jmv.26222.","journal-title":"J Med Virol."},{"issue":"6498","key":"132_CR37","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1126\/science.abc1560","volume":"368","author":"W Yin","year":"2020","unstructured":"Yin W, Mao C, Luan X, Shen D-D, Shen Q, Su H, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020;368(6498):1499\u2013504. https:\/\/doi.org\/10.1126\/science.abc1560.","journal-title":"Science."},{"issue":"7","key":"132_CR38","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1194\/jlr.R120000851","volume":"61","author":"SL Sturley","year":"2020","unstructured":"Sturley SL, Rajakumar T, Hammond N, Higaki K, M\u00e1rka Z, M\u00e1rka S, Munkacsi AB. Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity. J Lipid Res. 2020;61(7):972\u201382. https:\/\/doi.org\/10.1194\/jlr.R120000851.","journal-title":"J Lipid Res"},{"issue":"409","key":"132_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.canlet.2017.09.009","volume":"28","author":"J Lyu","year":"2017","unstructured":"Lyu J, Yang EJ, Head SA, Ai N, Zhang B, Wu C, et al. Pharmacological blockade of cholesterol trafficking by cepharanthine in endothelial cells suppresses angiogenesis and tumor growth. Cancer Lett. 2017;28(409):91\u2013103.","journal-title":"Cancer Lett"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00132-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-020-00132-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00132-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T23:19:26Z","timestamp":1626909566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-020-00132-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["132"],"URL":"https:\/\/doi.org\/10.1007\/s43440-020-00132-z","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"12 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest. Moshe Rogosnitzky is a named inventor on patents utilizing cepharanthine for treatment of androgenic alopecia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}